LUC00099I2 - - Google Patents

Download PDF

Info

Publication number
LUC00099I2
LUC00099I2 LU00099C LUC00099C LUC00099I2 LU C00099 I2 LUC00099 I2 LU C00099I2 LU 00099 C LU00099 C LU 00099C LU C00099 C LUC00099 C LU C00099C LU C00099 I2 LUC00099 I2 LU C00099I2
Authority
LU
Luxembourg
Application number
LU00099C
Other languages
French (fr)
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of LUC00099I1 publication Critical patent/LUC00099I1/fr
Publication of LUC00099I2 publication Critical patent/LUC00099I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LU00099C 2005-05-20 2019-02-06 LUC00099I2 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68347405P 2005-05-20 2005-05-20
EP06776035A EP2007814A2 (en) 2005-05-20 2006-05-19 Single domain vhh antibodies against von willebrand factor
PCT/EP2006/004773 WO2006122825A2 (en) 2005-05-20 2006-05-19 Single domain vhh antibodies against von willebrand factor

Publications (2)

Publication Number Publication Date
LUC00099I1 LUC00099I1 (enExample) 2019-02-12
LUC00099I2 true LUC00099I2 (enExample) 2019-12-27

Family

ID=37431613

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00099C LUC00099I2 (enExample) 2005-05-20 2019-02-06

Country Status (28)

Country Link
US (3) US7807162B2 (enExample)
EP (4) EP3243839A1 (enExample)
JP (1) JP4986997B2 (enExample)
KR (1) KR101414438B1 (enExample)
CN (1) CN101213214B (enExample)
AU (1) AU2006249090B2 (enExample)
BE (1) BE2019C503I2 (enExample)
BR (1) BRPI0609797B8 (enExample)
CA (2) CA2608873C (enExample)
CY (2) CY1122579T1 (enExample)
DK (1) DK2444424T3 (enExample)
ES (2) ES2852423T3 (enExample)
FR (1) FR19C1005I2 (enExample)
HU (2) HUE039846T2 (enExample)
IL (2) IL187168A (enExample)
LT (2) LT2444424T (enExample)
LU (1) LUC00099I2 (enExample)
MX (1) MX2007014564A (enExample)
NL (1) NL300966I2 (enExample)
NO (3) NO20076475L (enExample)
NZ (1) NZ563392A (enExample)
PL (2) PL3415535T3 (enExample)
PT (2) PT3415535T (enExample)
RU (1) RU2433139C2 (enExample)
SI (1) SI2444424T1 (enExample)
TR (1) TR201815552T4 (enExample)
WO (1) WO2006122825A2 (enExample)
ZA (1) ZA200709570B (enExample)

Families Citing this family (264)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512364T1 (de) 2002-08-07 2011-06-15 Ablynx Nv Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
US9320792B2 (en) * 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
SI1836500T1 (sl) * 2005-01-14 2010-11-30 Ablynx Nv Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
WO2008049881A2 (en) * 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
WO2008049897A1 (en) * 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US9156914B2 (en) 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
CN101663319A (zh) * 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
MX2009012650A (es) 2007-05-24 2010-02-18 Ablynx Nv Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
AU2008270274B2 (en) 2007-07-03 2012-06-28 Ablynx N.V. Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
CA2706425A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
CA2712432C (en) * 2008-01-29 2018-09-25 Ablynx N.V. Methods to stabilize single variable domains
US20110091462A1 (en) * 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
US20110158996A1 (en) * 2008-03-21 2011-06-30 Ablynx N.V. Von willebrand factor specific binders and methods of use therefor
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US9034325B2 (en) 2008-07-22 2015-05-19 Ablynx N.V. Amino acid sequences directed against multitarget scavenger receptors and polypeptides
ES2701649T3 (es) * 2009-01-14 2019-02-25 Ablynx Nv Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
CA2759370C (en) 2009-04-30 2020-02-11 Peter Schotte Method for the production of domain antibodies
ES2804450T3 (es) 2009-07-10 2021-02-08 Ablynx Nv Método para la producción de dominios variables
EP2473528B1 (en) 2009-09-03 2014-12-03 Ablynx N.V. Stable formulations of polypeptides and uses thereof
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US20120321640A1 (en) 2009-12-01 2012-12-20 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
HRP20251657T1 (hr) 2009-12-14 2026-02-13 Ablynx N.V. Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US20130012916A1 (en) 2010-02-11 2013-01-10 Glide Pharmaceutical Technologies Limited Delivery of immunoglobulin variable domains and constructs thereof
SI2533761T1 (sl) 2010-02-11 2019-08-30 Ablynx N.V. Postopki in sestavki za pripravo aerosolov
PH12012501744A1 (en) * 2010-03-03 2021-08-09 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2632946B1 (en) 2010-10-29 2017-12-06 Ablynx N.V. Method for the production of immunoglobulin single variable domains
PY1147875A (es) 2010-11-08 2015-08-03 Novartis Ag Polipéptidos de enlace de los receptores de quimiocina
AU2012234284B2 (en) 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
WO2012130872A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP3590950A1 (en) 2011-05-09 2020-01-08 Ablynx NV Method for the production of immunoglobulin single varible domains
US9505840B2 (en) 2011-05-27 2016-11-29 Ablynx N.V. Inhibition of bone resorption with RANKL binding peptides
EP3363813A1 (en) 2011-06-23 2018-08-22 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
EP4350345A3 (en) 2011-06-23 2024-07-24 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
AU2012273928A1 (en) 2011-06-23 2014-02-06 Ablynx Nv Immunoglobulin single variable domains directed against IgE
MY167125A (en) * 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
EP2753644A1 (en) 2011-09-09 2014-07-16 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
DE102011121238A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
DE102011121237A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
ES2715279T3 (es) 2012-05-24 2019-06-03 Vib Vzw Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores
UA113879C2 (xx) * 2012-06-08 2017-03-27 ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
DK2951201T3 (en) 2013-01-30 2018-01-08 Vib Vzw Novel chimeric polypeptides for screening and drug detection purposes
WO2014122183A1 (en) 2013-02-05 2014-08-14 Vib Vzw Muscarinic acetylcholine receptor binding agents and uses thereof
US9617339B2 (en) 2013-03-15 2017-04-11 Vib Vzw Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
EP3003372B1 (en) 2013-06-07 2019-10-09 Duke University Inhibitors of complement factor h
WO2014201400A2 (en) * 2013-06-13 2014-12-18 Biogen Idec Ma Inc. Anti-factor viii antibodies or uses thereof
WO2015121092A1 (en) 2014-01-30 2015-08-20 Vib Vzw Opioid receptor binding agents and uses thereof
EP3131929B1 (en) * 2014-04-16 2022-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
NL2013007B1 (en) * 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
PT3194976T (pt) 2014-07-22 2020-07-03 Univ Brussel Vrije Métodos para selecionar agentes que estabilizam complexos proteicos
PL3204018T3 (pl) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
ES3029413T3 (en) 2015-04-02 2025-06-24 Ablynx Nv Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
ES2984656T3 (es) 2015-05-13 2024-10-30 Ablynx Nv Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3
HRP20191800T1 (hr) 2015-05-13 2019-12-27 Ablynx N.V. Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti
US10639307B2 (en) 2015-05-15 2020-05-05 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
AU2016302768B2 (en) 2015-07-31 2019-08-22 Medimmune Limited Methods for treating hepcidin-mediated disorders
NO2768984T3 (enExample) 2015-11-12 2018-06-09
HUE057241T2 (hu) 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
US10544222B2 (en) * 2015-11-18 2020-01-28 Merck Sharp & Dohme Corp. PD1/CTLA4 binders
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
CN108473565B (zh) * 2015-11-18 2022-05-27 默沙东公司 Ctla4结合剂
CA3006398A1 (en) 2015-11-27 2017-06-01 Ablynx Nv Polypeptides inhibiting cd40l
US10626186B2 (en) * 2016-01-26 2020-04-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-VWF D'D3 single-domain antibodies and methods of use
WO2017191108A1 (en) 2016-05-02 2017-11-09 Ablynx Nv Treatment of rsv infection
US10975155B2 (en) * 2016-05-13 2021-04-13 Medimmune, Llc CD40L-Fc fusion polypeptides and methods of use thereof
HRP20251020T1 (hr) 2016-05-20 2025-10-24 Harpoon Therapeutics, Inc. Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2017220645A1 (en) 2016-06-23 2017-12-28 Ablynx N.V. Improved pharmacokinetic assays for immunoglobulin single variable domains
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP4442709A3 (en) 2017-01-17 2024-12-25 Ablynx NV Improved serum albumin binders
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
JP7186401B2 (ja) 2017-02-28 2022-12-09 フエー・イー・ベー・フエー・ゼツト・ウエー タンパク質の経口送達のための手段及び方法
WO2018178307A1 (en) 2017-03-31 2018-10-04 Ablynx N.V. Improved immunogenicity assays
US10865238B1 (en) * 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
KR20200005635A (ko) 2017-05-11 2020-01-15 브이아이비 브이지더블유 가변 면역글로불린 도메인의 글리코실화
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
SG10202107880XA (en) * 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
IL270951B2 (en) 2017-06-02 2025-05-01 Merck Patent Gmbh ADAMTS5, MMP13 and aggrecan-binding polypeptides
CN118085076A (zh) * 2017-06-02 2024-05-28 埃博灵克斯股份有限公司 结合聚集蛋白聚糖的免疫球蛋白
CN110997001A (zh) 2017-06-02 2020-04-10 默克专利股份有限公司 Mmp13结合免疫球蛋白
US11261260B2 (en) 2017-06-02 2022-03-01 Merck Patent Gmbh ADAMTS binding immunoglobulins
CA3070253A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP4635987A3 (en) 2017-10-31 2026-01-14 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
US20200199206A1 (en) * 2017-12-08 2020-06-25 AC Thera, LLC Bacterial toxin-neutralizing nanobodies and methods of making and using the same
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
US12037382B2 (en) 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
MX2020008294A (es) 2018-02-06 2020-11-18 Ablynx Nv Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
US20200392512A1 (en) 2018-02-26 2020-12-17 Ablynx N.V. Nucleotide sequences encoding peptide linkers
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
JP2021519093A (ja) 2018-03-27 2021-08-10 ユーエムシー ユトレヒト ホールディング ビー．ブイ． 微小血管血栓症の処置のための標的化血栓溶解
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
EP3946434A1 (en) 2019-04-02 2022-02-09 Immunetune B.V. Immune-stimulatory compositions and use thereof
CA3314168A1 (en) 2019-04-29 2026-08-05 Confo Therapeutics N.V. Screening methods and assays for use with transmembrane proteins, in particular with gpcrs
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
EP4631523A3 (en) 2019-05-01 2025-12-31 Novo Nordisk A/S ANTI-IL-6 ANTIBODY FORMULATION
WO2020232303A1 (en) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. EpCAM BINDING PROTEINS AND METHODS OF USE
EP3976067A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
US20220324947A1 (en) 2019-08-05 2022-10-13 Stichting Vu Identification and Elimination of HCMV-Infected Cells
WO2021039574A1 (ja) * 2019-08-23 2021-03-04 株式会社カネカ Ｏ結合型糖鎖修飾が抑制された重鎖抗体
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
US20220380456A1 (en) 2019-10-21 2022-12-01 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
CA3160506A1 (en) 2019-11-11 2021-05-20 Ibi-Ag Innovative Bio Insecticides Ltd. Insect control nanobodies and uses thereof
CA3158991A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2021123360A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
CA3173090A1 (en) 2020-02-25 2021-09-02 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
EP4144758A4 (en) 2020-04-22 2024-05-15 Mabwell (Shanghai) Bioscience Co., Ltd. SINGLE VARIABLE DOMAIN ANTIBODY DIRECTED AGAINST HUMAN PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) AND DERIVATIVE THEREOF
CA3177089A1 (en) * 2020-05-01 2021-11-04 Yi Shi Compositions and methods for identifying nanobodies and nanobody affinities
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
AU2021274836A1 (en) 2020-05-19 2023-01-05 Aarhus Universitet Lysm receptor motifs
US20230227580A1 (en) * 2020-06-26 2023-07-20 Monash University Anti-vwf antibodies and uses thereof
WO2022002880A1 (en) * 2020-06-29 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
AR122933A1 (es) 2020-07-10 2022-10-19 Novo Nordisk As Métodos para tratar la enfermedad cardiovascular
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063984A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
CA3205463A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Cea6 binding molecules and uses thereof
CA3205465A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Epcam binding molecules and uses thereof
US20240050569A1 (en) * 2020-12-18 2024-02-15 Bioardis, Llc Mesothelin binding molecules and uses thereof
WO2022133050A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Gpc3 binding molecules and uses thereof
CN116783218A (zh) * 2020-12-23 2023-09-19 努玛治疗有限公司 具有降低的免疫原性的抗体可变结构域和抗体
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
WO2022136693A1 (en) * 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
AU2021405066A1 (en) * 2020-12-23 2023-06-22 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
WO2022136649A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Non-blocking human ccr8 binders
CA3206125A1 (en) 2020-12-24 2022-06-30 Vib Vzw Murine cross-reactive human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
EP4288095A1 (en) 2021-02-05 2023-12-13 Vib Vzw Sarbecovirus binders
CN117241804A (zh) 2021-02-17 2023-12-15 非营利性组织佛兰芒综合大学生物技术研究所 在癌症治疗中slc4a4的抑制
US20250263490A1 (en) 2021-02-19 2025-08-21 Vib Vzw Cation-Independent Mannose-6-Phosphate Receptor Binders
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
WO2022216157A1 (en) 2021-04-09 2022-10-13 Stichting Radboud Universiteit Off the shelf proximity biotinylation enzyme
WO2022242892A1 (en) 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
CA3225194A1 (en) 2021-06-23 2022-12-29 Vib Vzw Means and methods for selection of specific binders
JP2024524378A (ja) 2021-06-29 2024-07-05 山▲東▼先声生物制▲薬▼有限公司 Ｃｄ１６抗体及びその応用
US20250336476A1 (en) * 2021-07-12 2025-10-30 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and sytems for nanobody humanization
EP4377352A2 (en) 2021-07-30 2024-06-05 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
US20240343803A1 (en) 2021-07-30 2024-10-17 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof
EP4381094B1 (en) 2021-08-03 2025-07-02 Wageningen Universiteit Argonaute-based nucleic acid detection system
AU2022345251A1 (en) * 2021-09-17 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
EP4428156A4 (en) 2021-12-03 2026-03-04 Shandong Simcere Biopharmaceutical Co., Ltd. ANTI-BCMA NANOBODY AND USE THEREOF
TW202342508A (zh) 2021-12-17 2023-11-01 比利時商艾伯霖克斯公司 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
WO2023125888A1 (zh) 2021-12-31 2023-07-06 山东先声生物制药有限公司 一种gprc5d抗体及其应用
EP4463479A1 (en) 2022-01-12 2024-11-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
EP4476250A1 (en) 2022-02-07 2024-12-18 Vib Vzw Engineered stabilizing aglycosylated fc-regions
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
US20250313611A1 (en) 2022-05-18 2025-10-09 Vib Vzw Sarbecovirus spike s2 subunit binders
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023236889A1 (zh) 2022-06-06 2023-12-14 山东先声生物制药有限公司 靶向bcma、gprc5d和t细胞的多特异性抗体及其应用
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
US20250304677A1 (en) 2022-07-04 2025-10-02 Vib Vzw Blood-Cerebrospinal Fluid Barrier Crossing Antibodies
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
US20240075068A1 (en) 2022-07-15 2024-03-07 Gadeta B.V. Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
AU2023313033A1 (en) 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
US20260159606A1 (en) 2022-09-27 2026-06-11 Vib Vzw Antivirals Against Human Parainfluenza Virus
US20260103529A1 (en) 2022-10-18 2026-04-16 Confo Therapeutics N.V. Amino Acid Sequences Directed Against the Melanocortin 4 Receptor and Polypeptides Comprising the Same for the Treatment of MC4R-Related Diseases and Disorders
EP4612180A1 (en) 2022-10-31 2025-09-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
US20260176369A1 (en) 2022-11-08 2026-06-25 Stichting Amsterdam UMC Activation Inducible Antigen Receptors for Adoptive Immunotherapy
JP2025537809A (ja) 2022-11-15 2025-11-20 アイメック・ヴェーゼットウェー 液滴操作のための方法およびシステム
EP4620974A1 (en) 2022-11-15 2025-09-24 Oricell Therapeutics Co., Ltd. Anti-afp/hla02 tcr-like antibody and use thereof
WO2024126805A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
EP4634232A1 (en) * 2022-12-15 2025-10-22 Institut National de la Santé et de la Recherche Médicale Single-domain antibody targeting von wilebrand factor a3-domain
EP4638472A1 (en) 2022-12-19 2025-10-29 UMC Utrecht Holding B.V. Btn2a1 binding peptide
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
US20260102527A1 (en) 2023-01-27 2026-04-16 Vrije Universiteit Brussel CD8b-BINDING POLYPEPTIDES
JP2026519901A (ja) 2023-01-27 2026-06-19 ヴィーアイビー ヴィーゼットヴィー Ｃｄ１６３結合複合体
EP4662246A1 (en) 2023-02-09 2025-12-17 Seni-Preps B.V. Immunoglobulin single variable domains that inhibit urease and use thereof
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
US20240344078A1 (en) 2023-03-14 2024-10-17 Aarhus Universitet Genetically altered nfr5 receptor kinases
JP2026519919A (ja) 2023-04-03 2026-06-19 ブイアイビー ブイゼットダブリュ 血液脳関門通過抗体
EP4709753A1 (en) 2023-05-11 2026-03-18 Vib Vzw Slc4a4/nbce1 inhibitors
WO2024240162A1 (en) 2023-05-23 2024-11-28 Shanghai Allygen Biologics Co., Ltd. Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
EP4719482A1 (en) 2023-06-05 2026-04-08 Vib Vzw Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2024251981A1 (en) 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
EP4731656A1 (en) 2023-06-23 2026-04-29 Vib Vzw Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
GB202314424D0 (en) 2023-09-20 2023-11-01 Cambridge Entpr Ltd A conjugate
WO2025061919A1 (en) 2023-09-22 2025-03-27 Ablynx Nv Bi- and multivalent albumin binders
AU2024373680A1 (en) 2023-11-03 2026-06-18 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
CN122438859A (zh) 2023-12-22 2026-07-21 阿布林克斯有限公司 用于核内递送的基于蛋白质的缀合载体
US20250236673A1 (en) 2023-12-22 2025-07-24 Ablynx N.V. Protein-based carriers for site-specific amine conjugation
WO2025154058A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025154056A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect cda nanobodies and uses thereof
WO2025167664A1 (zh) * 2024-02-07 2025-08-14 原启生物科技(上海)有限责任公司 Ror1抗原结合蛋白及其用途
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025196308A1 (en) 2024-03-22 2025-09-25 Vib Vzw Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025262150A2 (en) 2024-06-18 2025-12-26 Ablynx Nv Antibody-recruiting molecules
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use
WO2026027659A1 (en) 2024-07-31 2026-02-05 Seni-Preps B.V. Improved immunoglobulin single variable domains that inhibit urease and use thereof
WO2026109764A1 (en) 2024-11-22 2026-05-28 Novozymes A/S Stabilized solid formulation of antibodies

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5238919A (en) 1986-05-30 1993-08-24 Scipps Clinic And Research Foundation Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
ATE122238T1 (de) 1987-06-10 1995-05-15 Dana Farber Cancer Inst Inc Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU664561B2 (en) 1991-06-21 1995-11-23 University Of Cincinnati, The Orally administrable therapeutic proteins and method of making
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
WO1994002610A1 (en) 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
JPH08507070A (ja) 1993-02-22 1996-07-30 アルザ・コーポレーション 活性物質の経口投与のための組成物
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
GB9311454D0 (en) 1993-06-03 1993-07-21 Agricultural & Food Res Pharmaceutical compositions
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
CA2162878A1 (en) 1993-06-09 1994-12-22 Leon Gerardus Joseph Frenken Process for producing fusion proteins comprising scfv fragments by a transformed mould
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
CA2169298A1 (en) 1993-09-10 1995-03-16 Martin Chalfie Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
US5670132A (en) 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
ES2197210T3 (es) 1994-11-30 2004-01-01 Ajinomoto Co., Inc. Agente antitrombotico y anticuerpos monoclonales contra el factor von willebrand.
WO1996022307A1 (en) 1995-01-19 1996-07-25 The Research Foundation Of State University Of New York Genes encoding an insect calcium channel
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
DE69604298T2 (de) 1995-09-22 2000-05-18 Bioimage A/S, Soeborg Varianten des grünen fluoreszenzproteins, gfp
WO1997038102A1 (en) 1996-04-04 1997-10-16 Unilever Plc Multivalent and multispecific antigen-binding protein
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6350860B1 (en) 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
US5895466A (en) 1997-08-19 1999-04-20 At&T Corp Automated natural language understanding customer service system
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
ID26964A (id) 1998-02-19 2001-02-22 Xcyte Therapies Inc Komposisi dan metode untuk pengaturan pengaktifan limfosit
ATE535154T1 (de) 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
HUP9900956A2 (hu) 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
US6872538B1 (en) 1998-07-06 2005-03-29 Euroscreen S.A. High-throughput screening diagnostic and/or dosage method of an agonist and/or an antagonist for a calcium-coupled receptor
US6228360B1 (en) 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US6251393B1 (en) 1998-10-23 2001-06-26 The Brigham And Women's Hospital, Inc. Conformation-specific anti-von Willebrand Factor antibodies
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
BR9916765A (pt) 1999-01-05 2001-09-25 Unilever Nv Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico
ATE276359T1 (de) 1999-01-19 2004-10-15 Unilever Nv Verfahren zur herstellung von antikörperfragmenten
NZ513356A (en) 1999-02-05 2004-01-30 Univ Leiden Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate
US6419934B1 (en) 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
WO2000055318A2 (en) 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
CN1252264C (zh) 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原－结合蛋白抑制病毒感染
EP1190065A2 (en) 1999-06-18 2002-03-27 Cv Therapeutics, Inc. Atp binding cassette transporter protein abc1 polypeptides
EP1190260B1 (en) 1999-07-05 2011-01-26 K.U. Leuven Research & Development Detection of von-willebrand factor (vwf) activity
WO2001009300A2 (en) 1999-08-02 2001-02-08 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
ATE440111T1 (de) 1999-11-29 2009-09-15 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
ATE342922T1 (de) 1999-11-29 2006-11-15 Unilever Nv Immobilisierung von proteinen mit hilfe eines polypeptidsegments
ATE428733T1 (de) 2000-03-14 2009-05-15 Unilever Nv Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US6699473B2 (en) 2000-10-13 2004-03-02 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
AU2002229639A1 (en) 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
GB0031448D0 (en) 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
DE10105526B4 (de) 2001-02-07 2004-12-23 Robert Bosch Gmbh Verfahren zur Herstellung einer Klappenanordnung
CA2456121A1 (en) 2001-08-03 2003-02-20 Medical Research Council Intracellular antibodies
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US20050136056A1 (en) 2002-07-29 2005-06-23 Shunsuke Kageyama Pharmaceutical composition for the treatment of thrombocytopenia
ATE512364T1 (de) 2002-08-07 2011-06-15 Ablynx Nv Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
EP1565482B1 (en) 2002-10-23 2014-04-30 Ludwig Institute for Cancer Research Ltd. A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
SI1836500T1 (sl) 2005-01-14 2010-11-30 Ablynx Nv Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
LT2444424T (lt) * 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
WO2008049881A2 (en) 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
US20110158996A1 (en) * 2008-03-21 2011-06-30 Ablynx N.V. Von willebrand factor specific binders and methods of use therefor

Also Published As

Publication number Publication date
MX2007014564A (es) 2008-02-07
LUC00099I1 (enExample) 2019-02-12
WO2006122825A3 (en) 2007-10-04
NO20190279A1 (no) 2007-12-17
RU2007147381A (ru) 2009-06-27
BE2019C503I2 (enExample) 2025-12-10
EP2444424A1 (en) 2012-04-25
IL208607A0 (en) 2010-12-30
WO2006122825A9 (en) 2007-03-29
FR19C1005I2 (fr) 2020-01-31
LTPA2019504I1 (lt) 2020-07-27
EP2444424B1 (en) 2018-08-08
ZA200709570B (en) 2008-10-29
ES2852423T3 (es) 2021-09-13
JP2008539775A (ja) 2008-11-20
CN101213214B (zh) 2014-06-25
NO20076475L (no) 2008-02-18
PT3415535T (pt) 2021-02-02
US20100330084A1 (en) 2010-12-30
US20100022452A1 (en) 2010-01-28
NO345342B1 (no) 2020-12-21
WO2006122825A2 (en) 2006-11-23
BRPI0609797B8 (pt) 2021-05-25
CY1122579T1 (el) 2020-05-29
TR201815552T4 (tr) 2018-11-21
NZ563392A (en) 2009-12-24
CA2960105A1 (en) 2006-11-23
BRPI0609797A2 (pt) 2010-04-27
PL3415535T3 (pl) 2021-06-14
NL300966I2 (nl) 2019-04-11
AU2006249090A1 (en) 2006-11-23
DK2444424T3 (en) 2018-12-03
FR19C1005I1 (fr) 2019-03-22
US20130136736A1 (en) 2013-05-30
EP3415535B1 (en) 2020-12-09
PL2444424T3 (pl) 2019-01-31
BRPI0609797B1 (pt) 2018-07-03
AU2006249090B2 (en) 2012-08-23
HUS1900005I1 (hu) 2019-03-28
CA2608873A1 (en) 2006-11-23
CY2019006I2 (el) 2020-05-29
CY2019006I1 (el) 2020-05-29
LTC2444424I2 (lt) 2020-07-27
EP3243839A1 (en) 2017-11-15
PT2444424T (pt) 2018-11-09
EP3415535A1 (en) 2018-12-19
ES2694247T3 (es) 2018-12-19
US8372398B2 (en) 2013-02-12
NL300966I1 (nl) 2019-02-13
KR20080023301A (ko) 2008-03-13
KR101414438B1 (ko) 2014-07-10
JP4986997B2 (ja) 2012-07-25
AU2006249090A8 (en) 2006-11-23
CN101213214A (zh) 2008-07-02
IL187168A0 (en) 2008-02-09
SI2444424T1 (sl) 2018-10-30
NO2021020I1 (no) 2021-05-20
RU2433139C2 (ru) 2011-11-10
IL187168A (en) 2015-05-31
LT2444424T (lt) 2018-10-25
CA2608873C (en) 2017-04-25
US7807162B2 (en) 2010-10-05
HUE039846T2 (hu) 2019-02-28
EP2007814A2 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
BE2025C533I2 (enExample)
BE2023C529I2 (enExample)
BE2021C552I2 (enExample)
BE2021C557I2 (enExample)
BE2021C524I2 (enExample)
BE2021C519I2 (enExample)
BE2020C531I2 (enExample)
BE2020C511I2 (enExample)
BE2020C508I2 (enExample)
BE2019C521I2 (enExample)
BE2019C503I2 (enExample)
BE2018C037I2 (enExample)
BE2018C035I2 (enExample)
BE2018C019I2 (enExample)
BE2017C028I2 (enExample)
BE2019C533I2 (enExample)
BE2018C028I2 (enExample)
BE2017C007I2 (enExample)
BE2016C045I2 (enExample)
BE2016C022I2 (enExample)
BE2015C074I2 (enExample)
BE2014C012I2 (enExample)
BE2014C057I2 (enExample)
BE2013C074I2 (enExample)
BE2013C073I2 (enExample)